New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
08:06 EDTHRTXHeron selects HTX-011 as lead product for post-surgical pain program
Heron Therapeutics announced that it has selected HTX-011, a unique combination product utilizing its proprietary Biochronomer polymer-based drug delivery platform, as the lead product candidate for its post-surgical pain program. HTX-011 is designed to slowly release the local analgesic agent bupivacaine and the NSAID meloxicam locally at the site of the surgery over 3-5 days. By slowly delivering these agents directly to the location of the pain, lower doses can be used, which should result in greater efficacy with a lower risk of side effects. In a validated animal model, HTX-011 significantly reduced mean pain intensity compared to the current market leader, Exparel for up to 72 hours following surgery. Based on these results, the company has initiated a Phase 1 enabling toxicology study, to be followed by the initiation of a Phase 1 study in the fall.
News For HRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for HRTX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use